文献速递冠心病

检测限法肌钙蛋白出院策略与常规care的随机对照试验

Limit of detection of troponin discharge strategy versus usual care: randomised controlled trial.
PubMed 文献 · Heart · 2020-05-05

本研究为英国八家医院的随机对照试验,纳入急诊胸痛且计划排除急性冠脉综合征的成人患者629例,比较检测限法高敏肌钙蛋白联合非缺血心电图出院策略(LoDED)与常规排除策略。主要结局为到院4小时内出院且30天内无主要不良心脏事件,LoDED组46%达到,常规组37%,校正OR 1.58(95%CI 0.84-2.98)。初始高敏肌钙蛋白不可测者30天内无MACE。

要点

  • LoDED策略可使46%胸痛患者4小时内安全出院,优于常规组的37%。
  • 初始高敏肌钙蛋白不可测者30天内无主要不良心脏事件。
  • 与常规策略相比临床有效性可变,受系统因素影响。

核心结论

  • LoDED策略可使超过40%的胸痛患者安全早期出院,但与现有排除策略相比临床有效性可变,并受更广泛系统因素影响。

研究设计与样本

  • 英国八家医院的随机对照试验,纳入急诊胸痛、临床医生计划排除ACS、初始心电图非缺血且症状高峰在6小时内的成人患者,1:1随机至LoDED策略或常规排除策略。
  • 共随机632例,排除3例后分析629例,年龄53.8(SD 16.1)岁,41%为女性。

主要发现

  • 629例中7%在30天内发生MACE。
  • LoDED组309例中141例(46%)在到院4小时内出院且30天内无MACE,常规组311例中114例(37%),汇总校正OR 1.58(95%CI 0.84至2.98)。
  • 初始高敏肌钙蛋白不可测的患者无人在30天内发生MACE。

临床怎么用

  • 对于急诊胸痛、初始心电图非缺血且症状高峰在6小时内的患者,可考虑采用检测限法高敏肌钙蛋白联合心电图策略评估早期出院。
  • 初始高敏肌钙蛋白不可测者30天内无MACE,支持该策略的安全性。

局限性

  • 与常规策略比较的临床有效性可变,受更广泛系统因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The clinical effectiveness of a 'rule-out' acute coronary syndrome (ACS) strategy for emergency department patients with chest pain, incorporating a single undetectable high-sensitivity cardiac troponin (hs-cTn) taken at presentation, together with a non-ischaemic ECG, remains unknown. METHODS: A randomised controlled trial, across eight hospitals in the UK, aimed to establish the clinical effectiveness of an undetectable hs-cTn and ECG (limit of detection and ECG discharge (LoDED)) discharge strategy. Eligible adult patients presented with chest pain; the treating clinician intended to perform investigations to rule out an ACS; the initial ECG was non-ischaemic; and peak symptoms occurred <6 hours previously. Participants were randomised 1:1 to either the LoDED strategy or the usual rule-out strategy. The primary outcome was discharge from the hospital within 4 hours of arrival, without a major adverse cardiac event (MACE) within 30 days. RESULTS: Between June 2018 and March 2019, 632 patients were randomised; 3 were later withdrawn. Of 629 patients (age 53.8 (SD 16.1) years, 41% women), 7% had a MACE within 30 days. For the LoDED strategy, 141 of 309 (46%) patients were discharged within 4 hours, without MACE within 30 days, and for usual care, 114 of 311 (37%); pooled adjusted OR 1.58 (95% CI 0.84 to 2.98). No patient with an initial undetectable hs-cTn had a MACE within 30 days. CONCLUSION: The LoDED strategy facilitates safe early discharge in >40% of patients with chest pain. Clinical effectiveness is variable when compared with existing rule-out strategies and influenced by wider system factors. TRIAL REGISTRATION NUMBER: ISRCTN86184521.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Carlton EW, Ingram J, Taylor H, et al. Limit of detection of troponin discharge strategy versus usual care: randomised controlled trial. Heart. 2020. PMID: 32371401. doi:10.1136/heartjnl-2020-316692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。